NCT07622329
A Clinical Study to Evaluate JCXH-213 in the Treatment of Adults With Primary Immune Thrombocytopenia
StatusRecruiting
PhasePhase 1
Primary completion
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 2 versions: 2 with changes below. See every version on ClinicalTrials.gov ↗
Notable Recruitment opened Show 4 more changesShow less
- Eligibility criteria expanded, about 30 words
- Study completion moved earlier from Jun 30, 2027 to Dec 30, 2026
- Primary completion date changed from estimate of Aug 30, 2026 to Sep 2, 2026
- Secondary endpoints: details revised at 5 of 11 entries
- Study First Submitted
- Notable: the plan changed
Endpoints
Primary
Safety and tolerability of JCXH-213
Timeframe: The DLT observation period is 14 days after the first infusion of JCXH-213 (Day1-Day14).
Secondary (11)
Platelet count over time
Time to platelet response
Cumulative weeks of platelet response
Change in WHO bleeding score
Degree of disease control
Show 6 moreShow less
Changes in platelet autoantibodies
Peripheral blood B-cell subset profiling
Changes in peripheral blood JCXH-213 mRNA levels
Changes in peripheral blood CD19 CAR-positive cells
Changes in peripheral blood cytokine levels
Changes in anti-drug antibodies (ADA)
Arms and interventions
Dose Level (2 mg,4 mg)Experimental
Drugs: JCXH-213
Sites
1 site in 1 country
- General Hospital of Western Theater Command of PLAChengdu, Chengdu, China